Fundraising Fox
Cagent Vascular
Wayne, US · Founded 2014 · Delaware corporation · 105 employees on LinkedIn · 3 known investors
Find your way into Cagent Vascular
Sign up to see every warm intro you have to Cagent Vascular
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cagent Vascular team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cagent Vascular develops endovascular medical devices, including the Serranator PTA Serration Balloon Catheter, for the treatment of vascular disease. The company serves vascular surgeons and interventionalists in the medical device industry.
Founders & leadership
BW
Brian WalshChairman & Chief Executive OfficerWalsh joined Cagent Vascular's board as chairman in 2018 before taking on the chief executive role in 2024. He previously led IanTECH Inc. as president and CEO and headed Carl Zeiss Meditec's cataract technology business, and earlier served as president and CEO of Transcend Medical and VP of sales and marketing at XTENT.
MC
Matt CondronSVP of OperationsMatt Condron is Senior Vice President of Operations at Cagent Vascular, where he oversees global operations, supply chain management, contract manufacturing, and regulatory sterilization validation for the company's endovascular medical devices.
CL
Corey LatanisionSVP of Marketing & International SalesCorey Latanision is SVP of Marketing & International Sales at Cagent Vascular, which develops endovascular medical devices for the treatment of vascular disease.
PS
Peter SchneiderChief Medical Advisor, Co-Founder
CA
Carol A. BurnsNamed on SEC filing
FL
Fred LampropoulosNamed on SEC filing
DM
Dennis McGrathNamed on SEC filing
Board
CT
MM
Marc-Andre MarcotteBoard director
Investors · 3
US Venture Partnerslisted by US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
How we know: US Venture Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Astoria Health InvestorsreportedLas Vegas
How we know: offering press articles · press coverage · Not right? Tell us
U.S. Venture PartnersreportedMinneapolis
How we know: press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$155M disclosed across 8 of 9 rounds · 2014–2026
▶$24.5MraisedJun 2026 · 51 investors · Other Health CareRule 506(b)
▶$24.5MraisedJun 2026 · 51 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bruce Brumfield, Jr.Director
- Casey TanseyDirector
- Aaron GreenExecutive Officer
- Marc-Andre MarcotteDirector
- Tak CheungDirector
- Brian WalshExecutive Officer, Director
- Offering amount
- $41M
- Amount sold
- $24.5M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$28.7MraisedFeb 2024 · 26 investors · Other Health CareRule 506(b)
▶$28.7MraisedFeb 2024 · 26 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Brian WalshDirector
- Dennis McGrathExecutive Officer
- Casey TanseyDirector
- Marc-Andre MarcotteDirector
- Bruce J BlumfieldDirector
- Carol A. BurnsExecutive Officer, Director
- Offering amount
- $30.3M
- Amount sold
- $28.7M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedMay 2023 · 41 investors · Other Health CareRule 506(b)
▶$7.2MraisedMay 2023 · 41 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Brian WalshDirector
- Greg FreddeDirector
- Dennis McGrathExecutive Officer, Director
- Mike MarkertDirector
- Carol BurnsExecutive Officer, Director
- Peter SchneiderDirector
- Marc-Andre MarcotteDirector
- Offering amount
- $11M
- Amount sold
- $7.2M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.5MraisedJun 2021 · 11 investors · Other Health CareRule 506(b)
▶$9.5MraisedJun 2021 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Carol BurnsExecutive Officer, Director
- Mike MarkertDirector
- Peter SchneiderDirector
- Brian WalshDirector
- Dennis McGrathExecutive Officer, Director
- Marc-Andre MarcotteDirector
- Fred LampropoulosDirector
- Offering amount
- $9.5M
- Amount sold
- $9.5M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMay 2018 · 31 investors · Other Health CareRule 506(b)
▶$3MraisedMay 2018 · 31 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter SchneiderDirector
- Carol A. BurnsExecutive Officer, Director
- Brian WalshDirector
- Robert GiasolliDirector
- Fred LampropoulosDirector
- Dennis McGrathExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $3M
- First sale
- Jul 2017
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$50KraisedJun 2014 · 2 investors · Other Health CareRule 506(b)
▶$50KraisedJun 2014 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter SchneiderDirector
- Robert GiasolliDirector
- Dennis McGrathExecutive Officer, Director
- Carol A. BurnsExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $50K
- First sale
- Jun 2014
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Vantis VascularVantis Vascular develops vascular intervention technology, including the CrossFast integrated vascular delivery system with an auto-locking inner monorail microcatheter and outer delivery catheter for complex PCI procedures. Founded by physicians, the company is also developing next-generation intravascular lithotripsy (IVL) and peripheral below-the-knee (BTK) solutions for vascular interventionalists.</parameter>
<parameter name="founders">[{"full_name": "Jason Turner", "title": "Chief Executive Officer"}, {"full_name": "Tim Fischell", "title": "Chief Medical Officer"}, {"full_name": "Frank Saltiel", "title": "Chief Clinical Officer"}, {"full_name": "Gary McCord", "title": "Chief Commercial Officer"}, {"full_name": "Mike Mirizzi", "title": "Chief Technology Officer"}, {"full_name": "Marc Monahan", "title": "Chief Financial Officer"}]</parameter>
<parameter name="hq_city">San Jose
BDBD is a global medical technology company developing devices, systems, and solutions for medication administration, diagnostics, connected care, biopharmaceutical manufacturing, and interventional procedures. The company serves healthcare providers, laboratories, and biopharmaceutical manufacturers across diagnostics, drug delivery, surgical care, and patient monitoring.
AngiodynamicsAngioDynamics develops and manufactures medical devices aimed at treating serious diseases and improving patient outcomes. Founded in 1988, the company serves healthcare professionals and operates globally across North America, Europe, the Middle East, and South America.
Access VascularAccess Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.
Innova VascularInnova Vascular is a medical device company focused on the vascular space, led by a founder with a background in developing and commercializing vascular medical devices. The page provides limited detail about the company's specific products.
Companies working in the same space as Cagent Vascular.
In the news
Frequently asked questions
- What does Cagent Vascular do?
- Cagent Vascular develops endovascular medical devices, including the Serranator PTA Serration Balloon Catheter, for the treatment of vascular disease. The company serves vascular surgeons and interventionalists in the medical device industry.
- Who are Cagent Vascular's investors?
- Cagent Vascular's investors include US Venture Partners, Astoria Health Investors, U.S. Venture Partners.
- How much funding has Cagent Vascular raised?
- Cagent Vascular has disclosed $155M raised across 8 of its 9 known rounds.
- Where is Cagent Vascular headquartered?
- Cagent Vascular is headquartered in Wayne, US.